AOD-9604 vs Mazdutide
AOD-9604 and mazdutide differ in mechanism, trial maturity, and regulatory status. The cited studies do not establish a head-to-head efficacy ranking.
Last updated: September 28, 2026
Dossier labels summarize each dossier's research scope. They do not establish comparative treatment benefit or safety. Read the comparison below in that context.
AOD-9604
Dossier overview
Mazdutide
Dossier overview
What the evidence actually compares
AOD-9604 is a growth-hormone fragment derivative proposed for metabolic effects. It is not a GLP-1/glucagon receptor agonist.
FDA’s 2024 advisory-committee briefing describes the randomized OPTIONS phase 2b trial: 536 enrolled, 502 randomized, and no statistically significant weight-loss advantage over placebo at its week-12 primary endpoint or over 24 weeks. The full efficacy report was not a peer-reviewed publication in the reviewed set. This negative controlled human result matters more than proposed mechanisms or older animal findings. FDA AOD-9604 briefing
Mazdutide is a GLP-1/glucagon receptor dual agonist. Its published GLORY-1 and GLORY-2 weight trials enrolled Chinese adults; GLORY-2 included some adults with type 2 diabetes, whereas the separate US phase 2 trial enrolled adults without it. The trials used different follow-up and analysis methods. GLORY-1 · GLORY-2 · US phase 2
Innovent reports Chinese NMPA approvals for specified adult weight-management and type 2 diabetes uses. The reviewed source is a sponsor exchange filing, not an independently retrieved Chinese label. No US FDA mazdutide approval was verified; an FDA letter identifies one US seller’s mazdutide products as unapproved new drugs.
| Evidence question | AOD-9604 | Mazdutide |
|---|---|---|
| Mechanism | AOD-9604 is a growth-hormone fragment derivative proposed for metabolic effects. It is not a GLP-1/glucagon receptor agonist. | GLP-1/glucagon receptor dual agonist |
| Cited human weight evidence | OPTIONS phase 2b did not meet its weight endpoint | Published GLORY phase 3 studies in Chinese adults; separate US phase 2 study |
| US status in reviewed sources | No FDA approval verified | No FDA approval verified |
| China status in reviewed sources | No jurisdiction-specific conclusion from cited AOD-9604 sources | Innovent reports specified adult weight and diabetes approvals |
What cannot be inferred
Mazdutide’s published GLORY trials report within-trial weight effects against placebo in Chinese adults. AOD-9604’s OPTIONS result should not be treated as a smaller version of those effects; the substances, interventions and trial designs differ. GLORY-2 · FDA briefing
No FDA-approved AOD-9604 product was identified. FDA also flags potential immunogenicity and peptide-impurity concerns for compounded AOD-9604; that notice is a compounding-safety assessment, not efficacy evidence. FDA compounding notice The source for the AOD-9604 evidence above is this primary record; regulatory claims about mazdutide are supported by the linked sponsor filing and FDA letter. No combination-use claim follows from these separate studies.
This comparison is educational research context, not medical advice or a treatment protocol.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.